Thursday May 26, 2016 6:00PM Central European Summer Time - Recording Available
This program will review radiation therapy for lung cancer highlights from the recent 2016 European Lung Cancer Conference (ELCC) and European Society for Radiotherapy & Oncology (ESTRO) meetings.
Wednesday, May 11, 2016 at 7 p.m. Central European Summer Time - Recording Available
Although patients with oncogenic-addicted NSCLC respond to targeted therapies, invariably all became refractory to the treatment as a consequence of acquired resistance. Identification of molecular mechanisms responsible for therapy failure is of crucial relevance and many new agents and strategies are currently under development.
Tuesday, April 12, 2016 at 9 p.m. Eastern Daylight Time - Recording Available
This lecture will focus on cell free DNA in lung cancer. Topics covered will include the origin and biology of cell free DNA in this disease. Analytic and clinical validity studies, as well as evidence of clinical utility in medical decision making, will also be discussed.
Thursday, March 24, 2016 - 4 p.m. Central European Time - Recording Available
The IASLC Education Committee is pleased to announce the first program in the 2016 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Suresh Senan, MD, PhD, FRCR, and Wilko Verbakel, PhD, Ir, PEDng.
Thursday, March 10, 2016 - 7 p.m. Central European Time - Recording Available
Currently, the standard first-line treatment option for squamous cell NSCLC is cytotoxic chemotherapy (including cisplatin or carboplatin and a third-generation agent such as gemcitabine, taxanes, or vinorelbine.Targeted therapies have been tested in combination with cytotoxic chemotherapy but outcomes have been disappointing because of increased toxicity or lack of efficacy. Bevacizumab is contraindicated in patients with squamous histology tumours owing to a prohibitively high rate of severe pulmonary haemorrhage associated with bevacizumab treatment.
Wednesday, March 9, 2016 at 9 p.m. Eastern Standard Time - Recording Available
In this program, Dr. Lauren Averett Byers will discuss the current treatment of small cell lung cancer (SCLC) and review emerging therapies -- including novel targeted drugs and immunotherapies that are being investigated in clinical trials and in the lab. Recent results from clinical trials and translational studies in SCLC will be discussed, as well as representative case studies.
Friday, February 12, 2016 - 6 p.m. CET - Recording Available
The IASLC Education Committee is pleased to announce the first program in the 2016 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Ramesh Rengan, MD, PhD and Tony Wong, PhD, DABR.
Wednesday, February 10, 2016 - 7 p.m. CET - Recording Available
In patients with metastasized non-small-cell lung cancer (NSCLC) the current typical first-line treatment approaches are four cycles cisplatin and pemetrexed in patients with non-squamous cell carcinoma. As an alternative, centers still administer carboplatin, paclitaxel and bevacizumab and these are given for four to six cycles. Strategies of maintenance chemotherapy include "switch maintenance" with changing from four cycles carbo/pacli/bev or other non-pemetrexed combinations to maintenance pemetrexed until the time of progression and "continuation maintenance" with keeping single agent pemetrexed as ongoing treatment following four cycles of cisplatin and pemetrexed. Both strategies have been shown in large prospectively randomized phase-III trials (JMEN, PARAMOUNT) to significantly improve median overall survival at about three months as well as double the median PFS at very little costs of toxicity. This strategy has since become an important option to patients for the management armamentatium of metastasized non-small-cell lung cancer without any druggable driver mutation.
Wednesday, January 27, 2016 at 9 p.m. EST - Recording Available
IASLC continues the Lung Cancer Series in 2016 with this LIVE WEBINAR featuring Dr. John Heymach.
KRAS is the most common oncogenic driver in non-small cell lung cancer and other solid tumors. Despite great rapid recent progress in the treatment other oncogene-driven malignancies, to date there are still no targeted therapies for KRAS mutant lung cancers. A major obstacle to progress in this area is the heterogeneity among different KRAS tumors. Here, we discuss how co-occurring genomic alterations impact KRAS signaling and define distinct KRAS subgroups with different drug response patterns and immune profiles, and how such an understanding of Kras subsets can lead to development of more refined therapeutic approaches.